References

The Big Asthma Lie

Natural Asthma Treatment Systems

Get Instant Access

1 Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 1997; 31: 160-4.

2 Fletcher CM, Peto R, Tinker CM, Speizer FE. The Natural History of Chronic Bronchitis and Emphysema. Oxford: Oxford University Press, 1976.

3 Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEVj decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-64.

4 Seemungal T, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-13.

5 Postma DS, Steenhuis EJ, van der Weele LT, Sluiter HJ. Severe chronic airflow obstruction: can corticosteroids slow down progression ? Eur J Respir Dis 1985; 67: 56-64.

6 Postma DS, Peters I, Steenhuis EJ, Sluiter HJ. Moderately severe chronic airflow obstruction: can corticosteroids slow down progression? Eur Respir J1988; 1: 22-6.

7 Kerstjens HAM, Brand PLP, Hughes MD etal. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992; 327: 1413-19.

8 Renkema TEJ, Schouten JP, Köeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996; 109: 1156-62.

9 van Grunsven PM, van Schayck CP, Derenne JP etal. Long-term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999; 54: 7-14.

10 Derenne JP. Effects of high-dose inhaled beclomethasone on the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2-year prospective multicentre study. Am J Respir Crit Care Med 1995; 151: A463.

11 Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477-82.

12 Paggiaro PL, Dahle R, Bakran I et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773-80.

13 Vestbo J, Sorensen T, Lange P et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised, controlled trial. Lancet 1999; 353: 1819-23.

14 Pauwels RA, Löfdahl CG, Laitinen LA etal. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue to smoke. N Engl J Med 1999; 340: 1948-53.

15 Burge PS, Calverley PMA, Jones PW et al. Randomised, double-blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial. BMJ 2000; 320: 1297-303.

16 Seemungal TAR, Donaldson G, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.

17 Jarad NA, Wedzicha JA, Burge PS, Calverley PMA, ISOLDE study group. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999; 93: 161-6.

18 O'Brien A, Russo-Magno P, Karki A etal. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001; 164: 365-71.

19 Lung Health Study Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-9.

20 Anthonisen NR, Connett JE, Kiley JP etal. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 199^1; 272: 1497-505.

21 Lacoste JY, Bousquet J, Chanez P etal. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993; 92: 537-48.

22 Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am J Respir Crit Care Med 1997; 155:449-53.

23 Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with COPD. Am J Respir Crit Care Med2001; 164: 580-4.

24 Vestbo J. Another piece of the inhaled-corticosteroids-in-COPD puzzle. Am J Respir Crit Care Med 2001; 164: 514-15.

25 Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1267-71.

26 Dirksen A, Christensen H, Evald T et al. Bronchodilator and corticosteroid reversibility in ambulatory patients with airways obstruction. Dan Med Bull 1991; 38: 486-9.

27 Chanez P, Vignola AM, O'Shaugnessy T et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-34.

28 Pedersen B, Dahl R, Karlström R, Peterson CG, Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide: the impact of smoking. Am J Respir Crit Care Med 1996; 153: 1519-29.

29 Lenfant C, ed. Global Strategy for Asthma Management and Prevention: NHBLI/WHO Workshop Report Bethesda, MD: National Heart, Lung, and Blood Institute, 1995. (NIH Publication No. 95-3659.)

30 Wisniewski AF, Lewis SA, Green DJ et al. Cross-sectional investigation of the effect of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997; 52: 853-60.

31 Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8-14.

32 Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539-43.

33 Price MJ, Hurrell C, Medley HV, Efthimiou J. Cost-effectiveness of fluticasone propionate in the management of symptomatic COPD patients. Eur Respir J1999; 14 (Suppl. 30): 379s.

34 Price MJ, Hurrell C, Medley HV, Efthimiou J. Health care costs of treating exacerbations of chronic obstructive pulmonary disease (COPD). Eur Respir J 1999; 14 (Suppl. 30): 380s.

Was this article helpful?

0 0
Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook


Post a comment